Live Breaking News & Updates on Sara Zelkovic

Stay updated with breaking news from Sara zelkovic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , Mont Saint Guibert , Waals Gewest , New York , Walloon Region , Sara Zelkovic , Filippo Petti , Merck Co Inc , Exchange Commission , Communications Investor Relations , Lifesci Advisors , Chief Executive Officer , Private Securities Litigation Reform Act , Celyad Oncology , Annual Report , Media Contacts , Sci Advisors , Globe Newswire ,

Celyad Oncology Announces February 2022 Conference Schedule

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

Mont Saint Guibert , Waals Gewest , New York , United States , Walloon Region , Sara Zelkovic , Filippo Petti , Exchange Commission , Communications Investor Relations , Lifesci Advisors , Global Healthcare Conference , Celyad Oncology , Private Securities Litigation Reform Act , Annual Report , Media Contacts , Sci Advisors , Globe Newswire ,

Celyad Oncology SA: Celyad Oncology Announces February 2022 Conference Schedule

Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric ....

Mont Saint Guibert , Waals Gewest , New York , United States , Walloon Region , France General , Sara Zelkovic , Filippo Petti , Exchange Commission , Communications Investor Relations , Lifesci Advisors , Regulatory News , Euronext Nasdaq , Global Healthcare Conference , Celyad Oncology , Private Securities Litigation Reform Act , Annual Report , Media Contacts , Investor Relations Director , Sci Advisors ,

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

31.12.2021 - MONT-SAINT-GUIBERT, Belgium, Dec. 31, 2021 (GLOBE NEWSWIRE) - Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for . ....

Mont Saint Guibert , Waals Gewest , New York , United States , Walloon Region , Sara Zelkovic , Filippo Petti , Exchange Commission , Communications Investor Relations , Lifesci Advisors , Chief Executive Officer , Private Securities Litigation Reform Act , Celyad Oncology , Annual Report , Media Contacts , Sci Advisors ,

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) - Press Release

MONT-SAINT-GUIBERT, Belgium, Dec. 31, 2021 (GLOBE NEWSWIRE) Celyad Oncology SA ((Euronext &amp, NASDAQ:CYAD), a clinical-stage biotechnology co ....

Mont Saint Guibert , Waals Gewest , New York , United States , Walloon Region , Sara Zelkovic , Filippo Petti , Exchange Commission , Communications Investor Relations , Lifesci Advisors , Fortress Investment Group , Celyad Oncology , Belgian Law , Chief Executive Officer , Private Securities Litigation Reform Act , Annual Report , Media Contacts , Sci Advisors ,